Q2055 Idecabtagene vicleucel car
Q-Codes
Also known as: Abecma, idecabtagene vicleucel, CAR-T
Idecabtagene vicleucel CAR-T cell immunotherapy for CD19-positive multiple myeloma.
Clinical Context
First BCMA-targeting CAR-T approved for relapsed/refractory multiple myeloma. B-cell maturation antigen (BCMA) expressed on plasma cells.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.